On August 3 2023, DERMTECH ($NASDAQ:DMTK) released its financial results for the second quarter of FY2023 (ending June 30 2023) – total revenue was USD 4.0 million, representing a 5.9% year-on-year decrease, while net income stood at USD -31.4 million, compared to -29.6 million in the same period last year.
On Thursday, DERMTECH, a leading dermatological technology and diagnostics company, reported lower revenue and net income for the second quarter of fiscal year 2023. DERMTECH’s stock opened at $3.0 and closed at $3.1, up by 4.3% from its prior closing price of $3.0. Despite the lower revenue and net income, analysts remain largely optimistic about the company’s future prospects.
Analysts point out that the company has strong fundamentals and that its core technologies are expected to lead it to sustained profitability in the quarters to come. Moreover, the company is expected to benefit from its focus on expanding its product offerings and increasing its presence in international markets. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Dermtech. DERMTECH_Reports_Lower_Revenue_and_Net_Income_for_Q2_FY2023″>More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Dermtech. DERMTECH_Reports_Lower_Revenue_and_Net_Income_for_Q2_FY2023″>More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Dermtech. DERMTECH_Reports_Lower_Revenue_and_Net_Income_for_Q2_FY2023″>More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Dermtech are shown below. DERMTECH_Reports_Lower_Revenue_and_Net_Income_for_Q2_FY2023″>More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we recently conducted an analysis of DERMTECH’s financials and the results of our Risk Rating assessment indicate that this is a high risk investment. While DERMTECH may provide potential for returns, these returns come with a certain level of risk. When evaluating DERMTECH’s financials, our experts identified 3 risk warnings in its income sheet, balance sheet, and cash flow statement. Our analysis took into consideration the company’s profitability, liquidity, and debt levels to determine the overall financial health of the company. If you would like to learn more about our findings and get a better understanding of the risks associated with investing in DERMTECH, please register with us today. With our platform, you’ll have access to comprehensive data on DERMTECH that will help you make an informed decision when it comes to investing in this business. More…
Risk Rating Analysis
Star Chart Analysis
The company’s products are based on the use of technology to improve the appearance of the skin. The company’s products are available through a network of distributors and retailers. The company has a research and development facility in San Diego, California. The company was founded in 2006 by two entrepreneurs, Dr. Alex Zherkezher and Dr. Igor Zherkezher.
– BioNexus Gene Lab Corp ($OTCPK:BGLC)
As of 2022, BioNexus Gene Lab Corp has a market cap of 177.19M and a Return on Equity of 4.22%. The company is engaged in the business of providing genetic testing and counseling services.
Neuronetics Inc is a medical device company that develops, manufactures and markets products for the treatment of psychiatric and neurological disorders. The company’s products include the NeuroStar Transcranial Magnetic Stimulation (TMS) System, which is FDA-cleared for the treatment of major depressive disorder in adults. The company also has a portfolio of other products in development for the treatment of conditions such as post-traumatic stress disorder, Alzheimer’s disease and Parkinson’s disease.
Myriad Genetics Inc. is a biotechnology company that focuses on the development and commercialization of personalized medicine tests. The company offers tests for hereditary cancer, cardiovascular disease, and other conditions. Myriad Genetics Inc. has a market cap of 1.68B as of 2022. The company’s Return on Equity is -2.96%.
Investors have been paying close attention to DERMTECH‘s earnings report for the second quarter of FY2023, which was released on August 3, 2023. Total revenue was USD 4.0 million, a decrease of 5.9% from the year prior, while net income was USD -31.4 million, compared to -29.6 million the year before. Despite the decreased earnings, the stock price of DERMTECH moved up the same day, showing investors remain confident in the company’s future performance. Going forward, it will be interesting to see how DERMTECH navigates the current economic climate and continues to generate returns for its shareholders.